论文部分内容阅读
肝脏是结直肠癌远处转移的好发部位,一旦发生转移预后很差。随机临床研究证明结直肠癌术后门静脉灌注化疗(5-FU或5-FU/MMC)可预防肝转移。而门静脉化疗对患者抗肿瘤免疫功能的影响尚不清楚。本文旨在研究门静脉化疗对结直肠癌患者NK细胞活性的影响,进一步阐明结直肠癌术后门静脉化疗的利与弊。 1992～1994年作者将35例进展期结直肠癌患者随机分为2组,19人行术后门静脉化疗,15人作对照组,所有病人均行根治性切除术。伴有远处转移、其他严重疾病和已接受过上腹部手术者未列于本组研究。
The liver is a good site for distant metastasis of colorectal cancer, and the prognosis is poor once metastasis occurs. Randomized clinical studies have demonstrated that portal vein chemotherapy (5-FU or 5-FU/MMC) can prevent liver metastasis after colorectal cancer surgery. However, the effect of portal vein chemotherapy on the anti-tumor immune function of patients is not yet clear. This article aims to study the effect of portal vein chemotherapy on the activity of NK cells in patients with colorectal cancer, and further clarify the advantages and disadvantages of portal vein chemotherapy after colorectal cancer. From 1992 to 1994, the authors randomly divided 35 patients with advanced colorectal cancer into 2 groups. 19 patients underwent postoperative portal vein chemotherapy and 15 patients served as a control group. All patients underwent radical resection. Patients with distant metastases, other serious diseases and who have undergone abdominal surgery are not listed in this study.